Log in

Stealth BioTherapeutics News Headlines (NASDAQ:MITO)

$1.29
-0.03 (-2.64 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$1.23
Now: $1.29
$1.49
50-Day Range
$0.97
MA: $1.88
$3.07
52-Week Range
$0.90
Now: $1.29
$15.84
Volume90,800 shs
Average Volume689,660 shs
Market Capitalization$45.19 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Stealth BioTherapeutics (NASDAQ MITO) News Headlines

Source:
DateHeadline
 Analysts Expect Stealth BioTherapeutics Corp (NASDAQ:MITO) to Post -$0.04 EPS Analysts Expect Stealth BioTherapeutics Corp (NASDAQ:MITO) to Post -$0.04 EPS
www.americanbankingnews.com - March 24 at 12:10 AM
Stealth BioTherapeutics Corp (NASDAQ:MITO) Given Average Recommendation of "Hold" by BrokeragesStealth BioTherapeutics Corp (NASDAQ:MITO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 19 at 5:36 AM
Global Market for Cancer Therapies Could Exceed US$220 Billion by 2025Global Market for Cancer Therapies Could Exceed US$220 Billion by 2025
www.prnewswire.com - March 4 at 1:05 PM
INO, OMER, TLRY and PGEN among midday moversINO, OMER, TLRY and PGEN among midday movers
seekingalpha.com - March 3 at 2:37 PM
Stock Alert: Stealth BioTherapeutics Soars 108%Stock Alert: Stealth BioTherapeutics Soars 108%
www.nasdaq.com - March 3 at 2:37 PM
Why Stealth BioTherapeutics FDA Update Is a Big DealWhy Stealth BioTherapeutics FDA Update Is a Big Deal
www.msn.com - March 3 at 2:37 PM
Stealth Bio up 74% premarket on Rare Pediatric Disease tag for elamipretideStealth Bio up 74% premarket on Rare Pediatric Disease tag for elamipretide
seekingalpha.com - March 3 at 9:36 AM
FDA Grants Rare Pediatric Disease Designation to Stealth BioTherapeutics for Elamipretide for the Treatment of Barth SyndromeFDA Grants Rare Pediatric Disease Designation to Stealth BioTherapeutics for Elamipretide for the Treatment of Barth Syndrome
finance.yahoo.com - March 3 at 9:36 AM
Stealth BioTherapeutics to Present at 40th Annual Cowen Health Care ConferenceStealth BioTherapeutics to Present at 40th Annual Cowen Health Care Conference
finance.yahoo.com - February 27 at 6:53 PM
Stealth Bio up 34% premarket on "positive" elamipretide dataStealth Bio up 34% premarket on "positive" elamipretide data
seekingalpha.com - February 18 at 1:09 PM
Stealth BioTherapeutics Announces Positive Results From Study to Evaluate Efficacy of Elamipretide in Barth Patients Compared to Natural History ControlStealth BioTherapeutics Announces Positive Results From Study to Evaluate Efficacy of Elamipretide in Barth Patients Compared to Natural History Control
finance.yahoo.com - February 18 at 8:08 AM
Stealth Bio launches clinical development of SBT-272Stealth Bio launches clinical development of SBT-272
seekingalpha.com - January 21 at 11:51 AM
In wake of drug trial fail, Newton firm cuts most staff, top scientist quitsIn wake of drug trial fail, Newton firm cuts most staff, top scientist quits
finance.yahoo.com - January 9 at 7:00 AM
Stealth BioTherapeutics Corp. ADS (MITO) Institutional HoldingsStealth BioTherapeutics Corp. ADS (MITO) Institutional Holdings
www.nasdaq.com - January 5 at 10:41 PM
Stealth Bio cut to Neutral at H.C. Wainwright after PMM trial failureStealth Bio cut to Neutral at H.C. Wainwright after PMM trial failure
seekingalpha.com - December 23 at 10:23 PM
Mid-Day Market Update: Crude Oil Down Over 1%; Stealth BioTherapeutics Shares PlummetMid-Day Market Update: Crude Oil Down Over 1%; Stealth BioTherapeutics Shares Plummet
www.benzinga.com - December 20 at 1:51 PM
Is Stealth Bio Done After Mitochondrial Myopathy Study?Is Stealth Bio Done After Mitochondrial Myopathy Study?
www.msn.com - December 20 at 1:51 PM
Stealth BioTherapeutics stock falls on trial failureStealth BioTherapeutics' stock falls on trial failure
www.marketwatch.com - December 20 at 1:51 PM
Stealth BioTherapeutics' stock falls on trial failureStealth BioTherapeutics' stock falls on trial failure
finance.yahoo.com - December 20 at 1:51 PM
Stealth BioTherapeutics neuromuscular disorder drug fails late-stage studyStealth BioTherapeutics' neuromuscular disorder drug fails late-stage study
www.nasdaq.com - December 20 at 8:50 AM
Stealth Bios elamipretide flunks late-stage PMM studyStealth Bio's elamipretide flunks late-stage PMM study
seekingalpha.com - December 20 at 8:50 AM
Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial MyopathyStealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy
finance.yahoo.com - December 20 at 8:50 AM
Stealth Biotherapeutics to Present at Jefferies 2019 London Healthcare ConferenceStealth Biotherapeutics to Present at Jefferies 2019 London Healthcare Conference
finance.yahoo.com - November 19 at 7:13 PM
Stealth BioTherapeutics Corp (MITO) Q3 2019 Earnings Call TranscriptStealth BioTherapeutics Corp (MITO) Q3 2019 Earnings Call Transcript
www.nasdaq.com - November 14 at 7:15 PM
Stealth BioTherapeutics Corp. (MITO) CEO Reenie McCarthy on Q3 2019 Results - Earnings Call TranscriptStealth BioTherapeutics Corp. (MITO) CEO Reenie McCarthy on Q3 2019 Results - Earnings Call Transcript
seekingalpha.com - November 14 at 7:15 PM
Stealth BioTherapeutics Reports Third Quarter 2019 Financial Results And Recent Business HighlightsStealth BioTherapeutics Reports Third Quarter 2019 Financial Results And Recent Business Highlights
finance.yahoo.com - November 14 at 9:14 AM
Stealth Biotherapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019Stealth Biotherapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
finance.yahoo.com - November 11 at 1:00 PM
Stealth BioTherapeutics Corp. - American Depositary SharesStealth BioTherapeutics Corp. - American Depositary Shares
www.benzinga.com - October 24 at 11:32 PM
Stealth BioTherapeutics Presents Data for Elamipretide on Cardiac Function in Barth SyndromeStealth BioTherapeutics Presents Data for Elamipretide on Cardiac Function in Barth Syndrome
finance.yahoo.com - October 17 at 8:42 AM
Alexion (ALXN) Collaborates With Stealth BioTherapeuticsAlexion (ALXN) Collaborates With Stealth BioTherapeutics
finance.yahoo.com - October 11 at 10:46 AM
Company News For Oct 11, 2019Company News For Oct 11, 2019
finance.yahoo.com - October 11 at 10:46 AM
Stealth BioTherapeutics Presents Data on SBT-272 in NeurodegenerationStealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
finance.yahoo.com - October 7 at 12:34 PM
Stealth Biotherapeutics to Present at the 2019 Cantor Global Healthcare ConferenceStealth Biotherapeutics to Present at the 2019 Cantor Global Healthcare Conference
finance.yahoo.com - October 1 at 5:03 PM
Stealth BioTherapeutics to Attend Upcoming Investor ConferencesStealth BioTherapeutics to Attend Upcoming Investor Conferences
finance.yahoo.com - September 21 at 2:58 PM
Stealth BioTherapeutics Enters Oversold TerritoryStealth BioTherapeutics Enters Oversold Territory
finance.yahoo.com - September 17 at 8:13 PM
Stealth BioTherapeutics Sees Hammer Chart Pattern: Time to Buy?Stealth BioTherapeutics Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - September 13 at 11:03 AM
Stealth BioTherapeutics Announces Appointment of Robert Weiskopf as Chief Financial OfficerStealth BioTherapeutics Announces Appointment of Robert Weiskopf as Chief Financial Officer
finance.yahoo.com - September 3 at 8:46 PM
Stealth BioTherapeutics EPS beats by $0.04Stealth BioTherapeutics EPS beats by $0.04
seekingalpha.com - August 14 at 8:33 PM
Stealth BioTherapeutics Reports First Half 2019 Financial Results And Recent Business HighlightsStealth BioTherapeutics Reports First Half 2019 Financial Results And Recent Business Highlights
finance.yahoo.com - August 14 at 8:33 PM
Stealth BioTherapeutics: Targeting Primary Mitochondrial MyopathyStealth BioTherapeutics: Targeting Primary Mitochondrial Myopathy
seekingalpha.com - July 11 at 3:26 PM
Stealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial DisordersStealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial Disorders
finance.yahoo.com - July 2 at 9:18 AM
Stealth Biotherapeutics to Present at Upcoming Investor ConferencesStealth Biotherapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - May 30 at 8:08 AM
Stealth BioTherapeutics Reports First Quarter 2019 Financial Results And Recent Business HighlightsStealth BioTherapeutics Reports First Quarter 2019 Financial Results And Recent Business Highlights
finance.yahoo.com - May 15 at 8:27 PM
Stealth BioTherapeutics to Present at UBS Global Healthcare ConferenceStealth BioTherapeutics to Present at UBS Global Healthcare Conference
finance.yahoo.com - May 15 at 5:41 AM
Stealth Bios elamipretide shows positive action in early-stage AMD studyStealth Bio's elamipretide shows positive action in early-stage AMD study
seekingalpha.com - May 1 at 3:23 PM
Stealth BioTherapeutics Announces Positive Results for Elamipretide in Ophthalmic ConditionsStealth BioTherapeutics Announces Positive Results for Elamipretide in Ophthalmic Conditions
finance.yahoo.com - May 1 at 7:16 AM
Stealth Bio completes enrollment in late-stage elamipretide studyStealth Bio completes enrollment in late-stage elamipretide study
seekingalpha.com - April 26 at 3:22 PM
Stealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial MyopathyStealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial Myopathy
finance.yahoo.com - April 26 at 6:49 AM
Stealths elamipretide shows positive effect in Barth syndrome extension studyStealth's elamipretide shows positive effect in Barth syndrome extension study
seekingalpha.com - April 17 at 3:21 PM
Stealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension TrialStealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension Trial
finance.yahoo.com - April 17 at 6:46 AM
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel